Promising Phase 3 Results and Strategic Partnerships Drive Buy Rating for Arvinas

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $24.00.

Andrew Fein has given his Buy rating due to a combination of factors surrounding Arvinas Holding Company’s promising drug, vepdegestrant. The recent Phase 3 trial results for vepdegestrant, an oral PROTAC targeting ESR1-mutant patients, have shown a significant improvement in progression-free survival compared to the control group. This positions the drug well for regulatory approval as a second-line monotherapy, highlighting its potential in the competitive landscape of cancer treatments.
Moreover, the trial data suggests a favorable safety profile, with fewer severe adverse events and lower treatment discontinuation rates compared to competitors like elacestrant. As Arvinas navigates its partnership with Pfizer, the potential for milestone payments and strategic focus on its broader pipeline could further enhance its market position. These factors collectively contribute to Fein’s optimistic outlook and Buy rating for Arvinas’ stock.

In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $14.00 price target.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.